Amended Statement of Ownership (sc 13g/a)
February 13 2019 - 2:50PM
Edgar (US Regulatory)
United States
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. 5)*
HALOZYME
THERAPEUTICS, INC.
(Name of Issuer)
Common Stock
(Title of
Class of Securities)
40637H109
(CUSIP Number)
December 31, 2018
(Date of Event Which Requires Filing This Statement)
Check the
appropriate box to designate the rule pursuant to which this Schedule is filed:
☐ Rule
13d-1(b)
☒ Rule
13d-1(c)
☐ Rule
13d-1(d)
*
|
The remainder of this cover page shall be filled out for a reporting persons initial filing on this form
with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
|
The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities
Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
CUSIP No.
40637H109
|
|
|
|
|
|
|
1.
|
|
Names of
Reporting Persons
BB Biotech AG
|
2.
|
|
Check the Appropriate Box if a Member
of a Group (See Instructions)
(a) ☒ (b) ☐
|
3.
|
|
SEC Use Only
|
4.
|
|
Citizenship or Place of
Organization
Switzerland
|
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person
with:
|
|
5.
|
|
Sole Voting Power
0
|
|
6.
|
|
Shared Voting Power
8,322,860
|
|
7.
|
|
Sole Dispositive Power
0
|
|
8.
|
|
Shared Dispositive Power
8,322,860
|
9.
|
|
Aggregate Amount Beneficially Owned by Each Reporting Person
8,322,860
|
10.
|
|
Check if the Aggregate Amount in Row
(9) Excludes Certain Shares ☐
|
11.
|
|
Percent of Class Represented by amount
in Row (9)
5.8%
|
12.
|
|
Type of Reporting Person (See
Instructions)
HC, CO
|
Page 2 of 6
CUSIP No.
40637H109
|
|
|
|
|
|
|
1.
|
|
Names of
Reporting Persons
Biotech Target N.V.
I.R.S. Identification Nos. of above persons (entities only):
N/A
|
2.
|
|
Check the Appropriate Box if a Member
of a Group (See Instructions)
(a) ☒ (b) ☐
|
3.
|
|
SEC Use Only
|
4.
|
|
Citizenship or Place of
Organization
Curaçao
|
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person
with:
|
|
5.
|
|
Sole Voting Power
0
|
|
6.
|
|
Shared Voting Power
8,322,860
|
|
7.
|
|
Sole Dispositive Power
0
|
|
8.
|
|
Shared Dispositive Power
8,322,860
|
9.
|
|
Aggregate Amount Beneficially Owned by Each Reporting Person
8,322,860
|
10.
|
|
Check if the Aggregate Amount in Row
(9) Excludes Certain Shares ☐
|
11.
|
|
Percent of Class Represented by amount
in Row (9)
5.8%
|
12.
|
|
Type of Reporting Person (See
Instructions)
CO
|
Page 3 of 6
Item 2
2(a) Name of Person Filing:
BB Biotech AG (BB Biotech) on behalf of its wholly-owned subsidiary,
Biotech Target N.V. (Biotech Target)
2(b) Address of Principal Business Office or, if
none, Residence:
BB Biotech AG: Schwertstrasse 6,
CH-8200
Schaffhausen, Switzerland
Biotech Target N.V.: Ara Hill Top Building, Unit
A-5,
Pletterijweg Oost 1, Curaçao
2(c) Citizenship:
BB Biotech AG: Switzerland
Biotech Target N.V.: Curaçao
2(d) Title of Class of Securities
Common Stock, $0.001 par
value
2(e) CUSIP Number
40637H109
Item 4. Ownership
Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item
1.
|
(a)
|
Amount beneficially owned:
8,322,860
|
|
(b)
|
Percent of class:
5.8%
|
|
(c)
|
Number of shares as to which the person has:
|
|
(i)
|
Sole power to vote or to direct the vote
0
|
|
(ii)
|
Shared power to vote or to direct the vote
8,322,860
|
|
(iii)
|
Sole power to dispose or to direct the disposition of
0
|
|
(iv)
|
Shared power to dispose or to direct the disposition of
8,322,860
|
Item 10. Certification
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held
for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
Page 4 of 6
SIGNATURES
After reasonable inquiry and the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete
and correct.
|
|
|
|
|
|
|
BB Biotech AG
|
|
|
|
|
|
|
|
|
|
|
Date:
February 7, 2019
|
|
|
|
By:
|
|
/s/ Michael Hutter
|
|
|
|
|
|
|
Signatory Authority
|
|
|
|
|
|
|
|
|
Name:
|
|
Michael Hutter
|
|
|
|
|
|
|
|
|
Title:
|
|
Signatory Authority
|
|
|
|
|
Date:
February 7, 2019
|
|
|
|
By:
|
|
/s/ Ivo Betschart
|
|
|
|
|
|
|
Signatory Authority
|
|
|
|
|
|
|
|
|
Name:
|
|
Ivo Betschart
|
|
|
|
|
|
|
|
|
Title:
|
|
Signatory Authority
|
|
|
|
|
Biotech Target N.V.
|
|
|
|
|
|
|
|
|
|
|
Date:
February 7, 2019
|
|
|
|
By:
|
|
/s/ Michael Hutter
|
|
|
|
|
|
|
Signatory Authority
|
|
|
|
|
|
|
|
|
Name:
|
|
Michael Hutter
|
|
|
|
|
|
|
|
|
Title:
|
|
Signatory Authority
|
|
|
|
|
Date:
February 7, 2019
|
|
|
|
By:
|
|
/s/ Ivo Betschart
|
|
|
|
|
|
|
Signatory Authority
|
|
|
|
|
|
|
|
|
Name:
|
|
Ivo Betschart
|
|
|
|
|
|
|
|
|
Title:
|
|
Signatory Authority
|
Page 5 of 6
Exhibit Index
Exhibit A: Agreement by and between BB Biotech AG and Biotech Target N.V. with respect to the filing of this disclosure statement.*
*
|
Previously filed as an exhibit to BB Biotech AG and Biotech Target N.V.s Schedule 13G filed with the
Securities and Exchange Commission on August 7, 2014.
|
Page 6 of 6
Halozyme Therapeutics (NASDAQ:HALO)
Historical Stock Chart
From Apr 2024 to May 2024
Halozyme Therapeutics (NASDAQ:HALO)
Historical Stock Chart
From May 2023 to May 2024